Clinical to Commercial Sterile Injectables in 2026

Moving clinical to commercial sterile injectables from trial batches to market supply is one of the most demanding transitions in drug manufacturing. This injectable pharmaceutical manufacturing scale-up has to increase batch size, line speed and annual volume while never weakening sterility assurance, product quality or regulatory compliance. This guide explains how clinical to commercial manufacturing works for sterile injectables in 2026: the stages of the journey, the process validation and risk control that regulators expect and what manufacturing readiness really means before you commit to commercial supply.

What is the clinical to commercial transition for sterile injectables?

Clinical manufacturing produces small good manufacturing practice (GMP) batches for Phase I to Phase III studies, while the process is still being refined and flexibility matters more than throughput. Commercial manufacturing is the opposite: a validated, repeatable, high-volume process that delivers consistent quality batch after batch, for years.

The commercial supply transition is the controlled work that connects the two. It is where a process proven at clinical scale is redesigned, transferred, scaled and validated so it can run at commercial volume without compromising the sterility, potency or safety of the product. For injectables the transition is especially tight, because the product is delivered directly into the body and there is no room for microbial or particulate risk.

Why is injectable pharmaceutical manufacturing scale-up so challenging?

Sterile injectables combine engineering, regulatory and biological challenges at the same time. The most common manufacturing challenges in scale-up are:

• Sterility assurance at scale. Aseptic processing must hold as fill volumes, line speeds and batch durations grow. The revised EU GMP Annex 1 requires a documented Contamination Control Strategy, and every scale change has to be assessed against it.
• Process sensitivity. Mixing, homogeneity, filtration and fill accuracy behave differently in larger vessels and faster lines. What was robust at 30 litres may not be robust at 1,500 litres.
• Lyophilisation cycle scale-up. Freeze-drying cycles developed on small loads do not transfer linearly. Shelf loading, heat transfer and cycle time must be requalified for full commercial batches.
• Container closure integrity. Vials, syringes and ampoules have to remain a sterile barrier across the full shelf life, which must be demonstrated rather than assumed.
• Visual inspection at speed. Particulate and defect detection has to stay reliable as inspection moves from manual to high-speed automated lines.
• Extractables and leachables. Container and single-use system interactions need to be characterised for the commercial configuration.
• Biologics and complex molecules. Temperature sensitivity, aggregation and comparability add constraints, and cold chain has to be designed in from the start.
• Analytical method transfer. Release and stability methods must be transferred and revalidated so results are comparable across sites and scales.

The clinical to commercial pathway, stage by stage

A well-run programme treats process scale-up and technology transfer as a planned pathway rather than a last-minute step. The stages run in sequence, with quality risk management applied throughout:

1. Clinical manufacturing. GMP batches for Phase I to III at small scale, with the process still being optimised.
2. Process development and scale-up. The process is characterised and adapted for larger equipment and higher throughput.
3. Technology transfer. Process, analytical methods and documentation are transferred to the commercial site and scale.
4. Process validation. Process Performance Qualification batches confirm the process performs consistently at commercial scale.
5. Commercial supply. Routine production under continued process verification.

Process validation and risk control

In 2026 process validation follows the lifecycle approach set out by the United States Food and Drug Administration and EU GMP Annex 15, built on three stages:

1. Stage 1, Process Design. The commercial process is defined from development and scale-up knowledge, with critical quality attributes and critical process parameters identified.
2. Stage 2, Process Qualification. The facility, equipment and process are qualified, including Process Performance Qualification batches that demonstrate the process performs reliably at commercial scale.
3. Stage 3, Continued Process Verification. Ongoing monitoring confirms the process stays in a state of control during routine commercial supply.

Risk control runs across all three stages. Quality risk management under International Council for Harmonisation Q9 identifies and mitigates risks. Sterile-specific controls then provide the assurance regulators require: a Contamination Control Strategy aligned to Annex 1, aseptic process simulations (media fills), environmental monitoring, active restricted access barrier systems (RABS) or isolator technology, automated clean-in-place and sterilise-in-place systems, container closure integrity testing and sterility, endotoxin and bioburden testing. Stability studies run under International Council for Harmonisation conditions.

What manufacturing readiness really means

Manufacturing readiness is more than a validated process. Before committing to commercial supply, development leaders should confirm that:

• Capacity and equipment match the forecast, with headroom for growth.
• The supply chain, including raw materials and single-use systems, is secured and, where possible, dual-sourced.
• Inspection and packaging can scale with the fill process, so quality does not become the bottleneck.
• The quality system supports deviations, change control and documentation consistently across sites.
• Regulatory filings, stability data and site approvals are aligned with the launch timeline.

How to choose a CDMO for clinical to commercial sterile injectables

The right manufacturing partner reduces the number of handoffs, and every handoff is a risk to timeline and sterility assurance. When you evaluate a contract development and manufacturing organisation (CDMO) for the commercial supply transition, weigh these criteria:

• Does it offer an integrated sterile service covering aseptic fill-and-finish, lyophilisation, inspection and packaging in one network?
• Does it have experience across the full lifecycle, from clinical batches to validated commercial supply?
• Does it hold a strong regulatory track record, including European Medicines Agency (EMA) and United States Food and Drug Administration compliance and inspections by multiple health authorities?
• Can it run structured technology transfer with project management from feasibility to GMP production?
• Does it cover vials, prefilled syringes and ampoules, so the container decision is driven by the product rather than the site’s limits?

How Adragos supports the clinical to commercial journey

We operate an integrated sterile network built to take a product from clinical batches to commercial supply, combining aseptic fill-and-finish, lyophilisation, inspection and packaging. Across the group we run seven GMP facilities in the European Union, the United States and Japan, all GMP-certified and regularly audited by more than ten international health authorities, including support for regulated programmes in the United States. In practice that gives you:

• Liquid and lyophilised vials: aseptic fill-and-finish and lyophilisation for clinical and commercial supply, with vial filling up to 300 vials per minute and freeze-drying up to around 70,000 vials per batch, including complex formulations, aseptic compounding, biologics and controlled substances.
• Prefilled syringes: high-speed aseptic filling on RABS lines up to 540 syringes per minute, automated inspection up to 600 syringes per minute and six packaging lines including a plastic-free line.
• Ampoules: aseptic filling or terminal sterilisation, with formulation from 30 to 1,500 litres and capacity up to 120 million units per year.

We deliver this through a connected sterile network: Jura in Switzerland for liquid and lyophilised vials and aseptic fill-and-finish of small molecules and biologics; Maisons-Alfort in France for prefilled syringes, liquid and lyophilised vials, combining advanced aseptic filling, freeze-drying and inspection; Livron in France for ampoules with aseptic and terminal sterilisation; and Kawagoe in Japan for visual inspection, packaging and ampoule manufacturing to enter the Japanese market. Across clinical and commercial phases we provide GMP batches for Phase I to III and validated commercial production, with scalable inspection and packaging and project management from feasibility to GMP production. The model is deliberately simple for the customer: one point of contact, one governance and one quality mindset.

To plan a clinical to commercial route for a specific product, contact our sterile network team.

Frequently asked questions

What is the difference between clinical and commercial manufacturing?

Clinical manufacturing produces small GMP batches for Phase I to III trials while the process is still being refined. Commercial manufacturing runs a validated, repeatable process at high volume to supply the market consistently over the long term.

How many batches are needed for process validation?

There is no fixed number. Traditionally three Process Performance Qualification batches were used, but current guidance favours a risk and lifecycle based approach, so the number depends on process complexity and the level of process understanding.

What is technology transfer in injectable manufacturing?

Technology transfer is the structured handover of the manufacturing process, analytical methods and documentation from one scale or site to another, so the receiving site can produce the product reproducibly and to the same quality.

What changed with EU GMP Annex 1?

The revised Annex 1 places a Contamination Control Strategy at the centre of sterile manufacturing, requiring a holistic, documented approach to controlling contamination across facility, process and quality systems.

Which sterile injectable formats can be scaled to commercial supply?

The most common formats are liquid and lyophilised vials, prefilled syringes and ampoules. The right choice depends on the molecule, the dose, stability and the target market, and it is best decided with a partner that can manufacture all three.